Canada Markets open in 32 mins

Alpha Cognition Inc. (ACOGF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.8817+0.0217 (+2.52%)
At close: 03:20PM EST

Alpha Cognition Inc.

1228 Hamilton Street
Suite 301
Vancouver, BC V6B 6L2

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Frederick D. Sancilio M.S., Ph.D.Pres & Director496.58kN/A1950
Mr. Jeremy Christopher Wright C.M.A., CPA, CMA, CPAChief Financial Officer126.36kN/A1975
Dr. Denis G. Kay Ph.D.Chief Scientific Officer307.6kN/A1957
Mr. Kenneth Anthony Cawkell B.A., LL.B.Special Advisor & Director326.13kN/A1951
Mr. Michael E. McFaddenChief Exec. OfficerN/AN/A1967
Ms. Colleen JohnsSr. VP of Product Devel.N/AN/AN/A
Ms. Lauren D'AngeloChief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy program for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Corporate Governance

Alpha Cognition Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.